News

Synendos has been selected as a finalist of the Swiss Economic Award 2025

Synendos has been selected for the Bio-Neuroscience Award for the "Best Pitch"

Synendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510

Synendos is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch

Synendos featured in Scrip article

Synendos Therapeutics has been awarded with the Innosuisse Certificate

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022

In a last newsletter edition from NCCR Transcure, we can look behind the scenes of our technology transfer success story.

We are proud to announce that Synendos won TOP 100 Swiss Startup Public Voting Award 2021!

Scientific publication about the beneficial effect of the prototype SERI WOBE437 in a clinically relevant mouse model of Multiple Sclerosis and transient spasticity

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000)

EU reports on the successful SME Instrument Phase 1 grant received by Synendos

Award ceremony Venture Leaders 2019

Synendos won Venture Kick Stage III (CHF 100’000)

Synendos selected for the Innousuisse start-up core coaching program

Synendos received a co-fund from the European Union as part of the SME Instrument programme (EUR 50’000)

Synendos Therapeutics gets an Innobooster grant from Gebert Rüf Stiftung (CHF 150'000)

Synendos Therapeutics won Venture Kick Stage II (CHF 40’000)

Synendos Therapeutics selected among top10 finalist of >>venture>> competition

Synendos Therapeutics is among the finalists at the perfect pitch competition held at the BioTrinity London conference.